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Abstract: Hereditary dominant ataxias are a heterogeneous group of neurodegenerative conditions
causing cerebellar dysfunction and characterized by progressive motor incoordination. Despite
many efforts put into the study of these diseases, there are no effective treatments yet. Zebrafish
models are widely used to characterize neuronal disorders due to its conserved vertebrate genetics
that easily support genetic edition and their optic transparency that allows observing the intact
CNS and its connections. In addition, its small size and external fertilization help to develop high
throughput assays of candidate drugs. Here, we discuss the contributions of zebrafish models
to the study of dominant ataxias defining phenotypes, genetic function, behavior and possible
treatments. In addition, we review the zebrafish models created for X-linked repeat expansion
diseases X-fragile/fragile-X tremor ataxia. Most of the models reviewed here presented neuronal
damage and locomotor deficits. However, there is a generalized lack of zebrafish adult heterozygous
models and there are no knock-in zebrafish models available for these diseases. The models created
for dominant ataxias helped to elucidate gene function and mechanisms that cause neuronal damage.
In the future, the application of new genetic edition techniques would help to develop more accurate
zebrafish models of dominant ataxias.
Keywords: zebrafish; hereditary dominant ataxias; spinocerebellar ataxias; expanded repeats; X-
fragile; neurodegenerative disorders; genetic edition
1. Introduction
Hereditary ataxias are a heterogeneous group of neurodegenerative disorders with
clinical and genetic variability caused by dysfunction of the cerebellum and its afferent
and efferent connections, mainly involving the cerebellar cortex, the dentate nuclei and the
nuclei of the lower olive. In addition, degeneration of the Purkinje cells is a common feature
because they may be more susceptible to genetic or functional insults than other neuronal
cell types [1]. Ataxias are mainly characterized by slowly progressive incoordination of gait
and often associated with poor coordination of hands, speech, and eye movements [2,3].
Clinical classification was historically difficult due to similar neuropathology clinical
phenotype overlap. The development of molecular genetics allowed more accurate classifi-
cation of ataxias based on their genetics [4]. The inheritance of ataxias can be autosomal
dominant, autosomal recessive, X-linked or through maternal inheritance as part of a
mitochondrial genetic syndrome [2].
Autosomal dominant spinocerebellar ataxias (ADCAs) are late-onset disorders re-
stricted to the cerebellum and its connections, characterized by progressive gait and limb
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ataxia, variably associated with other non-neuronal and neurological symptoms such as
peripheral neuropathy, ophthalmoplegia, retinopathy, pyramidal and extrapyramidal signs,
dementia, and epilepsy [5,6]. ADCAs can be divided into spinocerebellar ataxias (SCAs),
of which 43 loci have been described at the present time, and episodic ataxias (EA), which
are seven different illnesses that can be distinguished by recurrent episodes of vertigo
and ataxia, variably associated with progressive ataxia [7,8]. In addition, there are other
conditions that have ataxia as a symptom that we will not discuss in this review.
Ataxia dominant related proteins have a wide range of functions including ion trans-
port, deubiquitination, phosphorylation, dephosphorylation, and regulation of transcrip-
tion and translation [6]. Alteration of their molecular pathways can cause neurotoxicity
as a consequence of protein aggregation, ARN toxicity, alterations in calcium homeosta-
sis, impaired proteostasis, mitochondrial stress, autophagy, apoptosis or deficits at the
DNA/RNA level causing problems in DNA repair or transcriptional dysregulation [3,7].
Pathology of autosomal dominant ataxias is caused by genetic mutations that can
be: polyglutamine expansions (e.g., CAG repeats), non-coding repeat expansions and
conventional mutations: missense, insertions and deletions [1]. Pathological expansion is a
common cause in dominant ataxias. Expansion diseases arise from normal polymorphic
repeats in the population that moved into the pathogenic range by de novo or hereditary
mutations. These deleterious expansions are believed to result in gain of function and the
length of the repeat expansion is related with the age of onset and disease severity. Severity
is increased in subsequent generations of a family in a process called anticipation Polyglu-
tamine expansions promote misfolding of the disease proteins and altered DNA-protein
or protein–protein interactions, which can cause transcription dysregulation, inhibition of
the function of histone acetyltransferases and the formation of cytoplasmic or intranuclear
neuronal polyglutamine aggregates. Non-coding repeat expansions are thought to cause
gain of function by RNA toxicity, disrupt splicing of essential genes and can be subjected
to RAN translation, resulting in the production of toxic protein species [1,9] (Figure 1).
Repetitive elements have not been very widely studied in fish, although it is known that
there are microsatellites in coding and noncoding positions but not if they have a role in
pathogenesis [10].
Figure 1. Repeat expansions in different ataxias.
As there are no effective treatments for dominant ataxias, animal models are useful for
gaining insight into the molecular and cellular mechanisms that cause neurodegenerative
disorders and helping to achieve the final goal of developing candidate therapies [11].
Despite all the research conducted with human cell models, these have the limitation of
lacking the complex nervous connections that are present in a complete central nervous
system (CNS) [12].
Zebrafish (Danio rerio) is an important model for biomedical research that presents
many advantages such as external fertilization, optic transparency of the embryos and
larvae and 76 to 82% of genes related with human disorders are present in zebrafish [13,14].
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The use of zebrafish in the study of neurodegenerative disorders is gaining popularity
because it has a similar general organization of CNS to humans, presenting molecular and
structural homology of the main brain areas and with most of its neuronal genes showing
similar functions [15]. In addition, its behavioral patterns are easy to analyze, allowing
the modeling of movement disorders, and it is useful for high-throughput screening of
chemicals/drugs because embryos/larvae easily absorb compounds through the skin [16]
(Figure 2).
Figure 2. Summary of the main tests that can be applied to zebrafish models of neuronal diseases.
Dorsal view of the brain to the left, female adult zebrafish in the center and a zebrafish embryo with
morphological defects to the right.
The development of zebrafish loss of function models is easily achieved by knock-
down with antisense morpholinos, which have a transient effect that remains for less than
a week [17,18], or stable knocks out with mutagens like N-ethyl-N-nitrosourea (ENU) [19]
or the recently developed CRISPR/Cas9 techniques [20]. Generation of gain of function
models is more difficult, because knock-in methods are less effective in zebrafish [21].
However, temporal gain of function models are easily created by the overexpression of
mRNAs [22].
Here, we used the classification of Bird [8] of dominant ataxias and dominant inherited
disorders related with ataxia to search in the zfin database (https://zfin.org/) and in the
PubMed database (https://pubmed.ncbi.nlm.nih.gov/) for potential zebrafish models
developed for these genes and corresponding disorders to review the most important
discoveries. We discuss the models of spinocerebellar ataxias (developed for SCA2, SCA3,
SCA6/episodic ataxia 2, SCA7, SCA13, SCA14, SCA17 and SCA37) and other ataxias
(sensory dominant ataxia 1, episodic ataxia 1 and episodic ataxia 5). We also review the
zebrafish models created for X-fragile/fragile-X tremor ataxia syndrome because, although
it is an x-linked ataxia, it is a gain of function disorder produced by repeat expansions. The
most relevant data of the ataxias discussed here are summarized in Table 1. The zebrafish
models reviewed here are summarized in Supplementary Table S1 (Table S1).
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Table 1. Summary of molecular mechanisms and clinical features of the ataxias discussed in this article.
Disease Gene Mutation Protein Function Clinical Features References





Progressive gait ataxia, dysarthria,
Parkinsonian
rigidity/bradykinesia, slow
saccadic eye movements, tremor,
muscle cramps, initial
hyperreflexia followed by early
hyporeflexia and myoclonus or
fasciculation-like movements
[23–26]









dystonia, rigidity and distal
muscle atrophies
[27,28]














Cerebellar ataxia, dysarthria and






Early or late onset cerebellar
ataxia with dysarthria often





in the Central Nervous
System















Pure cerebellar ataxia and,
distinctively, onset of dysarthria






Severe loss of proprioception
causing gait ataxia and a reduced
ability to feel pain, temperature









Early onset, spastic contractions
of skeletal muscle, recurrent
midline cerebellar dysfunction








Early onset, generalized epilepsy
and hereditary episodic ataxia [42]
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Table 1. Cont.































Late onset, cerebellar ataxia,
intention tremor, dementia,
parkinsonism and in sometimes
psychological symptoms
[47]
2. Materials and Methods
Articles were found in the zfin database (https://zfin.org/) by searching for zebrafish
models of genes that cause dominant ataxias and dominant inherited disorders related with
ataxia as described in the classification of Bird [8] and zebrafish models created for fmr1
gene (mutations on these gene causing X-fragile and fragile-X tremor ataxia syndrome).
The PubMed database (https://pubmed.ncbi.nlm.nih.gov/) was used to find ad-
ditional models related to these diseases (especially those created by overexpression of
repeated expansions) searching for “zebrafish” and “name of the disease”. The articles




Spinocerebellar ataxia type 2 is caused by CAG expansions in the gene ataxin-2
(ATXN2), which is an RNA-binding protein that interacts with the poly (A)-binding protein
and regulates mRNA stability [23–26].
Chantal Sellier and colleagues [48] generated the first zebrafish model related to
SCA2 while they were studying the c9orf72 gene, a gene responsible of amyotrophic lateral
sclerosis and frontotemporal dementia (ALS-FTD). First, they produced a knock-down of
c9orf72, which led to inhibition of autophagy and accumulation of cytoplasmic aggregates of
p62/sqstm1 and tdp-43. These are histopathological characteristics of ALS-FTD patients. The
combination of the c9orf72 knock-down with the expression of a HA-tagged construction of
intermediate atxn2 polyglutamine expansions (30 repeats), potentiated the aggregation and
neuronal cell death of atxn2. Zebrafish with depletion of c9orf72 and expression of 30 CAG
repeats had an abnormal motor behavior with reduced touch-evoked escape response. This
also disrupted arborization and caused shortening of motor neuron axons. Knock-down of
c9orf72 alone did not produce any locomotor phenotype, spinal motor neuron aberrations,
polyQ aggregation or toxicity. Combination of knock-down of c9orf72 with atxn2 with
normal polyglutamine length (22 repeats) did not produce these aggregates and neuronal
cell death. Additionally, the intermediate expansion of 30 repeats of CAG alone did not
produce toxicity in zebrafish. This suggests that intermediate polyglutamine expansions in
atxn2 might be a genetic modifier of ALS-FTD [48,49]. This is not a real model of SCA2,
because they only used intermediate expansions of atxn2 in combination of knock-down
of c9orf72. However, it is interesting that these studies found aggregation of intermediate
repeats of atxn2 that seem to be a result of dysregulation of the autophagy produced by
c9of72 reduction. Future generations of zebrafish models with pathological expansions
of more than 35 atxn2 repeats could reproduce the atxn2 aggregation and toxicity alone
without c9of72 knock-down.
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3.1.2. SCA3
Spinocerebellar ataxia type 3 (SCA3), also known as Machado–Joseph disease, is
a polyglutamine (polyQ) neurodegenerative disorder caused by abnormal (more than
40 repeats) CAG nucleotide repeat expansions in the ataxin-3 (ATXN3) gene, which encodes
a protein that is involved in ubiquitin-proteasome system degradation of proteins [27,28].
The first SCA3 zebrafish model was made by Liu and colleagues [50] by injecting
80 polyQ repeats mRNA in zebrafish embryos and showing that this caused apoptosis,
mainly in the CNS, at early developmental age. When they injected the atxn3 repeats in
a knock-out model of p53, neuronal degeneration was not observed. As P53 has known
functions in cycle arrest and apoptosis, this indicates that expression of atxn3 polyQ repeats
induces selective transcription/expression of p53 target genes and promotes p53-dependent
apoptosis in the CNS of zebrafish [50].
Maxinne Watchon and colleagues [51] generated the first transgenic SCA3 zebrafish
through the injection of 23 and 84 polyQ repeats. Atxn3-84Q zebrafish showed decreased
survival compared to atxn3-23Q and developed neuropathy with polyglutamine neuritic
beading-staining pattern in the medulla, atxn3 cleaved fragments, and motor impairment
that resulted in slower swimming. Potential drugs for treatment of SCA3 were found using
this mutant zebrafish. Calpeptin (a calpain inhibitor) decreased levels of atxn3 cleaved
fragments in atxn3-84Q zebrafish and rescued the motor phenotype, but it also removed
all ATXN3 expanded protein due to an increase in autophagic flux (indicated by reduced
p62 levels and increased LC3II levels) that cleared autolysosomes. Cotreatment with the
autophagy flux inhibitor chloroquine prevented the removal of human ATXN3 protein and
improved swimming [51]. Surprisingly, they did not study the cerebellum of transgenic
SCA3 zebrafish, and they only tested zebrafish of 1-year-old (i.e., middle aged) fishes, and
not older individuals in which neurodegeneration could be higher.
These results demonstrate the toxicity of atxn3 polyQ repeats, show the possible
relevance of calpeptin in the treatment of SCA3 and highlight the value of zebrafish as a
model to test drugs in expansion disorders.
More recently, an atxn3 morphant model resulted into small eyes with defective retinal
structure and disorganization of the microtubule cytoskeleton structure. The morphant
embryos that had a less severe phenotype had an alteration of the length of the outer
segment of photoreceptors and opsin mislocalization. Coinjection of human mRNA rescued
the phenotype but the coinjection of human mRNA with 14 or 80 repeats did not rescue
completely the phenotype. These data suggest a role for atxn3 in retinal ciliogenesis and
phagocytosis [52]. This could explain some cases of retinal alterations found in SCA3
patients [53–55].
3.1.3. SCA6 and Episodic Ataxia 2
Spinocerebellar ataxia type 6 (SCA6) is caused by mutations leading to CAG repeats
(20 or more) in the CACNA1A gene that encodes the α1A voltage-dependent calcium
channel subunit [29]. These channels are abundant in presynaptic terminals, mainly
in Purkinje cells of the cerebellum where they control neurotransmitter release [32]. In
addition, missense mutations in the CACNA1A gene are also associated with episodic
ataxia type 2 and hemiplegic migraine [43–45].
In zebrafish, the CACNA1A gene is duplicated into the cacna1aa and cacna1ab genes. A
knock-out model for cacna1ab showed progressive loss of touch-evoked motor behaviors
that was not explained by the lack of elements of touch-evoked circuit. Cacna1ab mutant
embryos had Rohon-Beard neurons and Mauthner cells with their normal projections.
However, touch-evoked activation was absent in cacn1ab mutant homozygous. Further-
more, heterozygous fish displayed an intermediate behavioral phenotype and the injection
of a splice blocking morpholino reproduced the homozygous phenotype [56]. A knock-out
model for cacna1ab showed reduced motility with weak and brief swimming bouts caused
by a defect in neuromuscular transmission in homozygous fishes. These defects in neu-
romuscular transmission are explained by reduced calcium trafficking at the presynaptic
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neuromuscular junctions. Treatment with 3,4-diaminopyridine (a K+ channel blocker)
and roscovitine (a P/Q-type channel agonist) rescued locomotion and neuromuscular
transmission [57].
Morpholinos for cacna1aa caused reduced locomotor activity, behavioral impairment
and epileptic-like seizures. Cacna1aa expression was detected in optic tectum and medulla
oblongata at 4 days post-fertilization (dpf) larvae. Larval cacna1aa knock-down increased
fish mortality probably due to defects in the brain, in the periphery, or both. Cacna1aa
morphants had remarkable morphological malformations: curved body axis, reduced
head and eye size, pericardial edema and yolk sac malformations. Peripheral effects of
loss of function of cacna1aa were evidenced by slight hyperpigmentation, lack of swim
bladder and shorter body length. Interestingly, these phenotypes have been also observed
in other zebrafish models of epilepsy [58,59]. Moreover, knock-down of cacna1aa induced
epileptiform-like effects in 90% of larval zebrafish. When antiseizure drugs were assessed
(sodium valproate, ethosuximide, lamotrigin and topiramate), the epileptiform-like events
of 4 dpf cacna1aa morphant larvae were significantly diminished [60].
Neural damage was observed in SCA6 zebrafish models. However, as SCA6 is a
dominant hereditary ataxia, more efforts in the study of heterozygous models such as that
developed by [56] or the creation of models of CAG repeats, will be necessary. However, as
point mutations are also associated with episodic ataxia 2, which sometimes is presented
with epilepsy [61], these models would help to learn more about molecular mechanisms
that cause loss of function of CACNA1A gene.
3.1.4. SCA7
Spinocerebellar ataxia type 7 (SCA7) is characterized by progressive neuronal loss
in the cerebellum and associated structures and loss of visual acuity due to loss of rod-
cone photoreceptors [30–33]. It is produced by CAG repeats in the N-terminal region of
ataxin-7 gene (ATXN7), which is a subunit of a multiprotein complex, the Spt-Ada- Gcn5-
acetyltransferase (SAGA) complex, that is involved in histone acetylation and transcription
regulation [62].
In zebrafish, morpholinos for atxn7 caused an increased embryonic lethality (most
of them died before 24hpf) combined with severe developmental defects like impaired
head and tail differentiation. Moreover, a small amount of morpholino was enough to
cause a marked disorganization of the photoreceptor layer and reduction of the number
of photoreceptors in the retina. In addition, atxn7 morpholinos impaired Purkinje and
granule cell differentiation. TUNEL assay at 5 dpf in atxn7 morphants revealed that the
reduced number of cerebellar neurons was not caused by increased levels of apoptosis.
The phenotype was rescued by coinjection of human ATXN7 mRNA [63].
Carrillo-Rosas and colleagues [64] inactivated the atxn7 gene with morpholinos and
CRISPR Cas9 and both models developed coloboma that was rescued by human ATXN7
mRNA coinjection. Atxn7 predominant expression in the ocular area already at 18 hours
post-fertilization (hpf) suggested extensive functions during eye development. Moreover,
dysfunction of atxn7 led to an increase in sonic hedgehog signaling and alteration of
proximo-distal patterning of the optic vesicle. Optic nerve formation was altered through
affectation of ganglion cell axon pathfinding and optic nerve bundling, which is consistent
with increased sonic hedgehog signaling. Photoreceptor terminal differentiation was also
altered due reduced expression of cone-rod homeobox protein [64].
The retina of zebrafish has been studied for a long time, and many mechanisms
involved in its development and function are known [65,66]. Therefore, these models offer
an easy and accessible way to study the function of atxn7 in neural and eye development
in zebrafish. In the future, it would be of interest to generate zebrafish models with the
CAG repeats to mimic better the genetics of SCA7.
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3.1.5. SCA13
Spinocerebellar ataxia type 13 (SCA13) is caused by missense mutations in the KCNC3
gene, which encodes the voltage-gated potassium channel Kv3.3 [34,35]. Kv3.3 channels
are highly expressed in Purkinje cells [67].
Zebrafish Kv3.3 channels exhibit strong functional and structural homology with
mammalian Kv3.3 channels. Human SCA13 mutations had similar effects on the activity of
zebrafish Kv3.3 channels [68]. The first zebrafish model of SCA13 was made by the injection
of human KCNC3 mRNA with a dominant negative R420H late onset subunit. Expression
of this mutation significantly suppressed the excitability of Kv3.3 expressing, fast-spiking
neurons in zebrafish. Although there were no gross locomotor deficits, precision and
amplitude of the startle response was significantly reduced at 55-60 hpf. These data
support the idea that changes in neuronal excitability initiate pathogenesis in SCA13 [69].
Differences in neuronal development in early or late onset SCA13 was studied with
the expression of infant or adult-onset mutant proteins in motor neurons in the zebrafish
spinal cord. Early onset human mutation (F448L) expressed in zebrafish caused recurrent
pathfinding failure of the caudal primary motor neurons, which sent long abnormal
collateral axons to inappropriate territories in the musculature. However, adult-onset
human mutation (R420H) in zebrafish did not produced pathfinding errors but contributed
to extend the complexity of the distal axonal arbor. These results seem to indicate that
early onset SCA13 is related with notable changes in the development of cerebellar neurons
that express Kv3.3 channels, which may contribute to the severe cerebellar atrophy seen in
affected infants [70].
A SCA13 zebrafish transgenic line coding an adult onset (R420H) human mutant
kv3.3 channel with specific expression in cerebellar Purkinje cells derived into a strong
degenerative phenotype linked to extensive Purkinje cell degeneration of their dendritic
and axonal structures. Movement deficits, as observed in SCA13 patients, were also
characterized by a significant reduction in numbers of saccade eye movements [71].
Differential excitability and viability of Purkinje cells in early onset and late onset mu-
tations was proved using zebrafish transgenic lines expressing infant onset or adult-onset
mutations in Purkinje cells. Zebrafish Purkinje cells expressing an early onset mutation
suffer a transient hyperexcitability shortly after Purkinje cells become spontaneously ac-
tive. This hyperexcitability stops the extension of Purkinje cell processes, altered dendritic
branching and synaptogenesis and resulted into cell death during cerebellar development.
This effect of infant-onset mutation reproduced the aberrant development and atrophy of
the cerebellum in early onset SCA13 patients. However, zebrafish Purkinje cells expressing
adult-onset mutation, matured normally and survived during cerebellar development.
Only a latent reduction in excitability was observed after an interval of evoked, high
frequency spiking. This resembles the phenotype of SCA13 adult-onset patients in which
cerebellar degeneration starts in adulthood [72]. The differences in Purkinje cell phenotype
of adult-onset mutation between this study, [72] and [71] could be explained by the expres-
sion of the mutant protein in [71], which might be the cause of Purkinje cell degeneration.
Toxicity of the aberrant protein might be a more decisive cause of late onset SCA13 than
latent Purkinje cell hypoexcitability.
These studies revealed the validness of the zebrafish model to study degeneration of
motor neurons and Purkinje cells caused by SCA13 mutations and elucidate the function of
Kv3.3 channels. Although zebrafish models reproduced differences in early and late onset
SCA13 mutations in excitability, pathfinding and viability of Purkinje cells, it would be
necessary to develop an adult zebrafish expressing late onset mutations to elucidate what
are the process that affect adult-onset cerebellar degeneration.
3.1.6. SCA14
Spinocerebellar ataxia type 14 (SCA14) [36] missense mutations in the PRKCG gene,
which encodes the γ-isoform of protein kinase C (PKCγ), causes increased kinase activity,
amyloid citotoxic aggregates and apoptosis via impairment of the ubiquitin proteasome
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system and induction of endoplasmic reticulum stress [73–75]. PKCs are involved in
intracellular signaling in numerous cellular processes. PKCγ is mainly expressed in the
CNS, being especially abundant in cerebellar Purkinje cells, and plays an important role in
synaptogenesis [75].
Patten et al. [76] studied with morpholinos if activation of PKCγ is required for the
developmental speeding of α-amino-3-hydroxyl-5-methyl-4-isoxazolepropionate receptor
(AMPA-R) that is necessary for correct maturation of glutamate synapses. They tested
the presence of PKCγ by recording miniature excitatory postsynaptic current (mEPSC) of
AMPA-R in presence of the drug Phorbol 12-myristate 13-acetate (PMA) and/or 5 mm
K+, which were seen to be capable of increasing AMPA mEPSC amplitude by activating
endogenous PKCγ [77]. In PKCγ morphants there was no effect on mEPSC amplitude,
demonstrating that PKCγ expression was reduced. When PKCγ wild-type mRNA was
injected with the morpholino, AMPA mEPSC amplitude was rescued. PKCγ morphants
failed to hatch out of the chorion and did not exhibit the C-start escape response. These
suggest that PKCγ activity is crucial for the proper behavioral development of zebrafish.
Additionally, there was no observed maturation of AMPA-Rs in the PKCγ morphants at
48hpf with respect to embryos at 33hpf. Increasing synaptic activity in 33hpf embryos
by application of an elevated K+ concentration or by application of N-methyl-d-aspartate
induces rapid PKCγ-dependent trafficking of fast AMPA-Rs to synapses. These results
seem to indicate that PKCγ is required for the normal developmental switch from slow
to fast AMPA receptors in embryonic zebrafish Mauthner cells and its deficiency causes a
failure in hatching and escape response [76].
The aim of the study by Patten et al. [76] was focused on understanding the function
of PKCγ on AMPA receptors. As far as we know, zebrafish models were not used for
study SCA14. Moreover, the PKCy mutation that produces SCA14 is a missense mutation,
the protein is formed but the mutation causes misfolding, aggregation and toxicity [75].
Therefore, knock-down with morpholinos may not be the best way to model the disease
and, knowing the advantages of the zebrafish as a model (see introduction), a mutant
model more representative of the human disorder would facilitate our understanding of
PKCγ function and SCA14 pathogenesis.
3.1.7. SCA17
Spinocerebellar ataxia type 17 (SCA17) is caused by CAG/CAA polyglutamine repeats
in the TATA-binding protein (TBP). TBP is an important general transcription initiation
factor and the DNA-binding subunit of RNA polymerase II transcription factor D [37].
In 2001, Müller and colleagues [78] studied the role of TBP and TLF (TBP-like factor)
in zygotic transcription in zebrafish. A Tlf model was generated with a dominant-negative
variant of TLF mRNA. Embryos injected with a dominant-negative variant of TLF mRNA
failed to initiate epiboly or arrested before dome stage. Additionally, expression of the
endogenous notail (ntl) transcription factor, which is characterized by a ring like expression
pattern at early gastrula stage embryos, was abolished in TLF injected embryos. Coinjection
of wild-type tlf, rescued the phenotype and also rescued ntl mRNA expression. Tbp
morphant embryos developed impaired epiboly and the phenotype was partially rescued
by the coinjection of mRNA of human TBP. However, ntl expression was not affected in
tbp morphant embryos. This suggests that tbp is not universally required for all zygotic
polymerase II transcription in the zebrafish embryo. Nevertheless, the similarities between
the two models seem to indicate that these two genes are essential during embryogenesis.
For this reason, the expression of seven early patterning genes (ntl, forkhead4, spadetail,
goosecoid, even-skipped1, sonic hedgehog and T-box6) was analyzed in both models. Tlf blocked
embryos abolished expression of all genes with the exception of even-skipped1, which
encodes a transcriptional repressor. Tbp morpholinos abolished the expression of five of
the seven genes excepting ntl and forkhead4. In conclusion, it was demonstrated that
tbp and tlf are required for epiboly in zebrafish embryos; although, they have different
functions [78].
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A subsequent deeper analysis of the same tbp knock-down model studied the function
and mechanisms of tbp in transcription and early embryo development [79]. For this,
they analyzed using microarrays the expression of 1927 genes at the dome stage in tbp
morphant embryos. 17.5% of these genes showed a significant reduction of expression
and a similar percentage (17.1%) had a significant increase. Meta-analysis of the ontogenic
stage-dependent gene expression array indicated that most of the genes that require Tbp
for their activation (77%) were principally stage-dependent and genes with reduced expres-
sion in tbp morphants showed the opposite tendency. A total of 23 GFP constructs using
promoters of zebrafish genes expressed at the sphere/dome-stage were tested to discern
whether Tbp regulates steady-state levels of mRNA in zebrafish through transcriptional or
post-transcriptional mechanisms. Seven promoters displayed Tbp-dependent promoter
activation, which confirms the suggested function of Tbp in activation of zygotic transcrip-
tion of some genes during development. Four promoters showed an increase of promoter
activity upon loss of tbp, which suggests a negative regulatory role of Tbp on the tbp gene
promoter and support previous observed inverse correlation between tbp mRNA and Tbp
protein levels at the late blastula and early gastrula stages [80]. In addition, the contribution
of tbp to maternal mRNA degradation was demonstrated by searching maternal expressed
genes in the tbp morphant microarray gene sets compared with an independent set of
662 maternal mRNAs and with the quantification of the expression of some maternal
transcripts in morphants and controls. Maternally inherited transcripts were significantly
upregulated in tbp morphants, which could indicate that the upregulation might be due to
the specific loss of degradation of many maternal mRNAs. The use of a synthetic maternal
mRNA smad2 injected in cell embryos, allowed to observe its fate. Microinjected smad2
mRNA was more efficiently degraded in control embryos than in tbp morphants, which
demonstrated that the increase of smad2 mRNA levels in tbp morphants is due to the loss
of degradation of smad2 mRNAs. Embryos treated with a-amanitin at a concentration that
inhibits Pol II showed higher levels of maternal genes similarly to tbp morphants. Finally,
miR-430 microRNA mediated maternal mRNA degradation was observed to be specifically
affected in tbp morphants when microarray data was analyzed and miR-430 target genes
showed upregulation in tbp morphants [79].
Although function of tbp in transcription and early embryonic development was
demonstrated, the role in neurodegeneration was not tested in these zebrafish studies.
The development of models that express CAG/CAA expansions would be useful for
that purpose.
3.1.8. SCA37
Spinocerebellar ataxia type 37 (SCA37) is caused by the pentanucleotide repeated
insertion ATTTC between ATTTT/AAAAT repeats in the non-coding region of the reelin
adaptor protein DAB1, which is necessary for brain patterning and synaptogenesis [38].
Injection of the pathological allele insertion (ATTTC)58 in zebrafish embryos re-
sulted in significant cell death that was not be observed in the normal N(ATTTT)7 and
N(ATTTT)139 alleles, suggesting an RNA-mediated toxicity mechanism [38].
The function of reelin, DAB1 and VLDLR (very low-density lipoprotein receptor),
which are part of reelin signaling pathway, was later studied using zebrafish knock-out
mutants. Specifically, these studies analyzed the role of these genes in synaptic lam-
ina formation [81], behavioral phenotype [82] and the formation of the cerebellum and
cerebellum-like structures [83].
Reelin signaling pathway during synaptic lamina formation was studied using mu-
tants of pathway members DAB1 and VLDLR. Loss of function of reelin signaling pathway
members critically disrupted lamina targeting of retinal ganglion cells axons and periven-
tricular neurites in the tectal neuropil. Vldlr expression was restricted to the ganglion
cell layer of the retina. There are two paralogous of DAB1 in zebrafish, of which dab1a
expression was found in retinal ganglion cells and dab1b in amacrine cells. CRISPR/Cas9
knock-out of dab1a resulted in abnormal retinal ganglion cell lamina targeting and increased
Cells 2021, 10, 421 11 of 21
arbor thickness in comparison with wild-type, although the phenotype was less severe than
in reelin and vldlr mutants. Periventricular neurons with lamination defects were found
to be increased in reelin, dab1a and vldlr mutants compared with wild-type. Transplanted
retinal ganglion cells from wild-type into reelin mutants suffer serious laminar targeting
defects when they innervate the tectal neuropil, although ganglion cell axons from reelin
mutants into wild-type targeted correctly the single lamina in the neuropil. However,
transplanted retinal ganglion cell axons from wild-type into dab1a and vldlr mutants did
not exhibit laminar targeting defects. By studying reelin signaling it was also observed that
reelin, dab1a and vldlr zebrafish mutants increase the average thickness of retinal ganglion
cell projections into deep layers compared to wild-type. Overexpression of vldlr caused
a significant reduction of retinal ganglion cells into deep layers, an effect no observed
when vldlr was overexpressed in reelin mutants, which means that this had to be due
reelin signaling [81]. Interestingly, VLDLR mutations have been associated with recessive
cerebellar hypoplasia characterized by cerebellar ataxia, mental retardation, strabismus,
dysarthria and seizures [84].
As abnormal Reelin signaling has also been observed in psychiatric disorders like
autism [85], schizophrenia [86,87], bipolar disorder [86], and Alzheimer’s disease [88],
the behavior of mutants for reelin, dab1a and vldlr was analyzed [82]. Reelin protein was
confirmed to be expressed in a restricted pattern in the adult zebrafish brain, including the
cerebellum with the exception of Purkinje and molecular cell layer. When reelin mutants
were put in a social preference tank they displayed a selective reduction in their preference
for social novelty in absence of global changes to social interactions, in contrast with
wild-type and heterozygous embryos. In open field test wild-type, heterozygous and
homozygous mutants for reelin spent a similar amount of time in the side and center of
the tank, indicating that reelin homozygous exploration, anxiety behavior and aggression
altered. Dab1a and vldlr mutants instead, exhibit a different behavioral phenotype. Dab1a
mutants were hyperactive and more aggressive. Vldlr mutants had more exploratory
behavior and less anxious behavior without being hyperactive. The different phenotypes in
dab1a and vldlr mutants in comparison with the reelin mutant indicates that social behavior
in reelin mutants is not mediated by the canonical reelin signaling pathway. In addition,
levels of 5-HT in the hindbrain were seen to be increased in Reelin mutants by HPLC. When
levels of 5HT were reduced with buspirone (5HT-1A receptor agonist), the interaction of
the wild-type with unfamiliar fish increased while the mutant phenotype was not rescue.
This means that at least in part 5HT signaling is involved in the preference for social [82].
The role of reelin in the positioning of the cerebellum and of cerebellum-like structures
was also studied with reelin, dab1a and vldlr zebrafish mutants. Although no abnormalities
were observed in the development of Purkinje cells or in layer formation in these mutants
at 5dpf, adult mutant fish showed atypical Purkinje cell positioning in the cerebellum.
Additionally, the proportion of ectopic Purkinje cells was higher in these mutants than in
wild-type, which suggests that reelin, dab1a and vldlr are required for proper migration
of Purkinje cells but not for their differentiation. Abnormal afferent axonal projections of
parallel fibers and climbing fibers in dendrite regions of the ectopic Purkinje cells were
found in the three mutant fishes. Ectopic eurydendroid cells and Bergmann glial cells were
observed in reelin mutants, suggesting that reelin is involved in positioning of both cells.
Abnormalities in cerebellum-like structures of the mesencephalic tectum were observed
as aberrant parallel fibers in deeper regions near the ectopic type I neurons. Purkinje
cells were observed in reelin mutants where they extended one or multiple neurites in
aberrant directions. At 30dpf, more Purkinje cells were found in the granular cell layer
in comparison with wild-type. Reelin was found in the tectum, cerebellum, and crista
cerebellaris in parallel fibers, suggesting that reelin is transported in parallel fibers. When
parallel fibers were ablated with laser, the localization of reelin was perturbed in the crista
cerebellaris, which means that parallel fibers are necessary for the distribution of reelin at
least in the dorsal hindbrain [83].
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The studies of the role of reelin, dab1 and vldlr in synaptic lamina formation, behavioral
phenotype and in the positioning of the cerebellum and cerebellum-like structures were
important to determinate the function and mechanisms of these genes. However, to focus
research on modeling SCA37, it would be necessary to analyze more deeply the zebrafish
embryos with pathological ATTTC expansions and investigate the mechanism by which
these expansions cause the observed aberrations.
3.2. Other Dominant Ataxias
3.2.1. Autosomal Dominant Sensory Ataxia 1
A missense mutation in RNF170, a ubiquitin E3 ligase gene, has been related to
autosomal dominant sensory ataxia 1, which was found in two families from Canada [39].
In addition, biallelic mutations in RNF170 were reported to cause autosomal recessive
hereditary spastic paraplegia [89].
Injection of rnf170 morpholino in zebrafish caused abnormalities and cell death before
1dpf in a dose dependent manner. Injection of RNF170 human mRNA with the mutation
caused developmental abnormalities in 79% of the embryos while injection of wild-type
RNF170 mRNA caused anomalies only in 18% of the embryos. Coinjection of the two
mRNAs resulted in an intermediate proportion of disturbed embryos, 45%. These results
suggested that RNF170 mutation has a gain of function toxic effect even in the presence of
the endogenous gene function [39].
Wagner et al. [89] used morpholinos against rnf170 which resulted in microphthalmia,
microcephaly and loss of motility at 48hpf. Acetylated-tubulin immunostaining, revealed
reduced neurogenesis in rnf170 morphants, especially in the mid-hindbrain region, and
reduced motor neuron axon staining in the myotome. Hematoxylin-eosin staining of trans-
verse cranial sections of 4dpf larvae revealed loss of ventricular cavities in rnf170 morphants.
Touch-evoked motility assay revealed loss of movement. Interestingly, coinjection with
wild-type human RNF170 mRNA exacerbated the developmental phenotype. Overexpres-
sion of human wild-type RNF170 mRNA in wild-type embryos as in Valdmanis et al. [39]
caused a moderate to severe phenotype in 50% of the embryos characterized by trunca-
tion of the body axis and reduction in eye size, while injection of pathological variants
related with autosomal recessive hereditary spastic paraplegia did not cause an abnormal
phenotype [89].
Although these assays with rnf170 morpholinos caused neuronal degeneration and
loss of movement, they did not ideally reproduce the autosomal dominant sensory ataxia 1.
Zebrafish mutant models should be developed to support the morpholino discoveries and
to gain new knowledge about this illness.
3.2.2. Episodic Ataxia 1
Episodic ataxia 1 is caused by missense, nonsense and splice site mutations in the
KCNA1 gene, which produces a potassium channelopathy. Short-lived attacks of ataxia
and sometimes epilepsy characterize this disorder [40,41].
Kcna1a zebrafish morphants were used as a drug screening platform to search an-
tiseizure therapies. Bioenergetics measurements revealed increase in basal respiration,
total mitochondrial respiration and ATP-linked respiration in kcna1a morphants but not in
control zebrafish of 3dpf. This increase of basal respiration was not due to effects on the
apoptosis pathway as was demonstrated with the coinjection of p53 morpholino. Moreover,
kcna1a morphants displayed hyperactivity when they were breed in darkness and EEG
abnormal activity consistent in repetitive high frequency, large-amplitude spikes. A total of
23 antiseizure drugs that block elevated metabolism have been screened using this model;
15 of these compounds effectively restored basal respiration, maximum respiratory capacity
and total mitochondrial respiration in kcna1a morphants to wild-type levels. A total of
870 compounds have been screened for their ability to significantly reduce hyperactive
swimming behaviors. Vorinostat, an histone deacetylase inhibitor, was found to be a candi-
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date drug to treat epilepsy, as it ameliorated bioenergetics measurements and significantly
reduced seizures [90].
This Kcna1a morphant model seemed to reproduce some of the characteristics of
episodic ataxia 1, although it was used only to study the epileptic phenotype. A future
characterization of the model to search for more features of episodic ataxia 1 would be
necessary. Furthermore, an efficient screening of antiseizure drugs was established based
on the increased metabolism and seizures of the kcna1a model. This enabled the discovery
of a candidate compound that would be useful for treating epilepsy. However, the creation
of a mutant model would be a better approach.
3.2.3. Episodic Ataxia 5
Episodic ataxia 5 is an extremely rare early-onset disease whose symptoms are gener-
alized epilepsy and hereditary episodic ataxia. Missense mutations in calcium-channel b4
subunit gene (CACNB4) cause episodic ataxia 5 [42].
Ebert et al. [91] generated knock-downs in the cancb4a and cancb4b zebrafish genes to
analyze if Ca2+ channel function is required for epiboly. Although cell division occurred
normally in morphant blastoderms beyond this stage both cancb4a and cancb4b morphants
developed three distinct types of phenotypes. Morphants of the most severe phenotype
(class I) failed to initiate blastoderm epiboly with a ring of dead cells near the blastoderm
margin, which caused the death of the embryos. Class II morphants initiated epiboly, but
progressed slowly, with occasional cell death at the blastoderm margin. Surviving class
II morphants developed severe morphological defects with extensive cell death in CNS
and all died at 24 hpf. Class III (less severe) embryos died with cardiac defects at 6dpf.
Injection of human mRNA of CACNB4 rescued the phenotypes. Surprisingly, using a
human cRNA incapable of binding calcium channels restored epiboly and coexpression
of the mutations in xenopus oocytes. This led to the conclusion that cancb4a and cancb4b
functions in epiboly were independent of Ca2+ channel activity. As cancb4a and cancb4b
were expressed in blastoderm and yolk, injection of morpholinos in the yolk at 1000 cell
stage produced embryos with class I phenotypes but in lower proportions than when
injected in one cell stage embryo injections. Labeling the yolk of morphant embryos with
the fluorescent reagent Sytox Green showed that the yolk syncytial layer had abnormal
disorganized nuclei at the sphere stage when morphant morphology appeared normal.
Nocodazole treatment, which is a microtubule disruptor, induced similar defects into yolk
syncytial layer nuclei that knock-down embryos, which suggests that morphant zebrafish
had a failure in microtubule polymerization [91].
Cancb4a and cancb4b morphants exhibited a dramatic lethal phenotype that did not
reproduce the symptoms related with episodic ataxia 5. However, they help to understand
the functions of cancb4a and cancb4b in epiboly and understanding the underlying molecu-
lar/cellular processes is of critical importance for the development of novel therapeutic
strategies. A zebrafish mutant model might reproduce better the epilepsy and ataxia
characteristics of episodic ataxia 5.
3.3. X-Fragile and FXTAS
Mutations on FMR1 can produce two syndromes, depending on the penetration
and number of CGG repeats in this gene that suppress the expression of the protein.
Full mutation alleles with more than 200 CGG repeats develop X-fragile syndrome [46].
Premutation alleles on FMR1 with 55 to 200 CGG repeats, present more frequently in carrier
males than in females, cause fragile-X tremor ataxia syndrome (FXTAS) [47].
Morpholino knock-down of fmr1 in the zebrafish brain caused disorganization and
morphological changes in the midbrain/hindbrain boundary. Anterior extension of the
head seemed to be incomplete in some fmr1 morphant embryos at 24hpf. At 48hpf, some
morphants displayed expanded brain ventricles and pericardial edema. Using a ventral
telencephalon/diencephalon marker (dlx-2a) and a midbrain/hindbrain boundary marker
(fgfr1), an altered pattern of transcription of both markers could be observed in fmr1
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morphants. Furthermore, an occasional axial defect was revealed in fmr1 morphants.
Coinjection with fmr1 mRNA, modified to lack fmr1 morpholino target sites, rescued the
phenotype. Neurite branching in Rohon–Beard neurons in fmr1 morphants was observed
to be increased (2-fold). Moreover, an 8-fold increase in rare axon guidance defects was also
reported. Neurite branching was also observed in axons of the trigeminal ganglion neurons.
Treatment with MPEP, a metabotropic glutamate receptor (mGluR) antagonist, rescued the
branching effects. Interestingly, treatment with MPEP in wild-type embryos resulted in
significant simplification of neurite branching and reduction in branch termination. These
data suggest that Fmr1 function influences neurite morphogenesis by facilitating mGluR
signaling. Craniofacial anomalies were examined using Alcian blue staining. Meckels’
cartilage was significantly shorter and wider in fmr1 morphants in comparison with wild-
type. Treatment of fmr1 morphants with MPEP returns the length and width of Meckels’
cartilage close to normal. In addition, reduced level of innervation of the facial region by
the cranial nerves was also observed in fmr1 morphants. As cranial ganglia and Meckels’
cartilage share a common origin in the neural crest, this suggests that these defects might
be due to defective neural crest specification, migration or differentiation. Examination
of neural crest-derived structures revealed significantly reduction of trigeminal ganglion
neurons in fmr1 morphants compared to wild-type larvae. However, MPEP treatment and
fmr1 mRNA injected embryos had increased number of trigeminal neurons in the ganglion
than wild-type larvae. Defects in neural crest specification were found in fmr1 morphants
at 26-somite stage and migration of neural crest cells was found to be different in fmr1
morphants than in wild-type. These data suggest that fmr1 has a key role in specification
and migration of a subset of neural crest cells [92].
In contrast to the morpholino study, two knock-out fmr1 models created with TILLING
were viable, developed into fertile adults, and did not display any phenotype. No cranio-
facial defects or Rohon-Beard neurite branching defects were observed [93]. Behavioral
analysis in one of these two fmr1 knock-out zebrafish lines revealed anxiolytic responses in
fmr1 mutants which spend significant more time in white compartment than wild-type and
increased locomotion upon a light/dark test. Inhibitory avoidance test showed impaired
inhibitory avoidance in fmr1 mutants. Moreover, speed and distances moved were higher
in fmr1 knock-out fishes than in wild-type in an open field test, which demonstrated the
presence of hyperactivity. Electrophysiological recordings from telencephalic slice prepara-
tions of adult fishes exposed significant reduction in long-term potentiation and enhanced
long-term depression in fmr1 mutants compared with wild-type fish, which suggested that
fmr1 mediates telencephalic synaptic plasticity [94]. Subsequent research on adaptation of
fmr1 adult mutants to a novelty environment over a twenty-minute period in open field
test, revealed reduced neophobic responses. Fmr1 mutants travelled longer distances in the
first 10 minutes of open field test (considered time of habituation of a novel environment)
than wild-type fishes, but after this time only vertical activity increased. This increase
in travel distances of fmr1 mutants in the first 10 minutes of the test was proposed to be
due to reduced neophobia and not due to hyperactivity. In addition, analyzing turning
behavior and movement patterning did not detect stereotypic behaviors. Moreover, fmr1
mutants swam to deeper levels than wild-type in a tank with a white bottom, beyond
the neophobic phase and preferred transparent walls. This was proposed to be a result
of altered explorative behavior or reduced open space aversion instead of reduced white
aversion [95]. A study of social behavior in fmr1 mutants reported precocious development
in shoaling preference at 28dpf in fmr1 mutants. Light/dark test revealed elevated anxiety
levels in fmr1 mutants, which spent a higher percentage of time in the light zone at 14dpf
and had a reduced number of midline crossings than wild-type. A novelty test showed
that 14dpf zebrafish spent more time in the upper tank (which means reduced anxiety),
but at 28hpf showed a decrease in time spent in the upper tank compared to wild-type [96].
Alteration of auditory processing in fmr1 zebrafish mutants that were hypersensitive to
sound was also reported [97]. Fmr1 mutant larvae hypersensibility to sound could be a
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result of hyperactivity of the thalamus [97]. Fmr1 patients also reveal enhanced evoked
electrophysiological responses to sound [98].
Moreover, the function of FMRP in neural circuit formation was studied by Shamay-
Ramot et al. [99] in the same model of fmr1 knock-out. First, they tested if mRNA target
genes mTor and sash1, which are related with FMRP, were affected and fmr1 mutants
were observed to have an increased expression of both genes. Locomotion was assessed
into 6dpf fmr1 knock-out larvae revealing hyperlocomotor activity under light and dark
conditions and altered behavioral response to light stimuli. Fmr1 mutant embryos of 2dpf
had expanded length of the motor axon arbors of 59% and increased number of branches of
120% compared to wild-type embryos. Total synaptic density in the axons of spinal motor
neurons increased by 53% in fmr1 knock-out embryos. Rohon-Beard sensory neurons also
had increased arbor length and number of branches of 73% and 92%, respectively, in fmr1
mutants in comparison with wild-type. Synapse density was not affected in Rohon-Beard
neurons of fmr1 mutants. Glutamatergic neurons had a 30% increase in synapse density
in fmr1 mutants. Expression of Adar enzymes, which have functions in RNA editing,
were measured in fmr1 mutants. Co-immunoprecipitation of Fmrp and Adar2a proteins
revealed biochemical interaction. RNA immunoprecipitation assays showed that Fmrp
protein can bind adar1 mRNA. Moreover, RT-qPCR of the four zebrafish adar genes revealed
overexpression of all these genes in fmr1 mutants. Western blot analysis of Adar2 protein
showed a 30% increase in expression levels in fmr1 mutant brains in comparison with
wild-type brains. Analyses of RNA editing target sites revealed a mild increase in RNA
editing of Adar target genes with synaptic and neuronal functions in fmr1 mutant larvae of
6dpf. Tissue specific changes of RNA editing levels were observed when the same genes
were analyzed in adult brains. These data suggest that Fmrp-mediated RNA editing plays
a role in the plasticity of neuronal circuits [99]. Furthermore, a role of fmr1 in myelin sheath
development was demonstrated in the same fmr1 mutant line in which its oligodendrocytes
developed smaller myelin sheaths. Reduced myelin basic protein expression was also
observed in fmr1 mutant larvae [100].
Recently, fmr1 mutant larvae created by CRISPR/Cas9 technology showed hyper-
activity, learning and memory defects and impaired craniofacial cartilage development.
In addition, genes related with memory function and cartilage development were found
downregulated in fmr1 mutants by RT-qPCR. Injection of wild-type fmr1 mRNA rescued
the phenotype [101].
A knock-down line created by DNAzyme reproduced some features of X-fragile such
as structural deformities (craniofacial abnormalities, bent notochord and deformed tail)
increased anxiety, impaired cognition and caused repetitive behavior (circling) at 7dpf.
Moreover, mGluR5 protein, a direct target of FMRP increased. This model was used to
find an accurate time window of treatment. Treatment in 0-3dpf window obtained the best
results. Early treatment of the fmr1 knock-down embryos with mavoglurant, an mGluR5
antagonist, reduced anxiety, increased cognition and reduced circling at 7dpf. Treatment
with KU046 (an anxiolytic) in the 0-3dpf window also reduced anxiety and repetitive
behavior at two doses [102].
These models revealed important functions of Fmrp, reproduced most of the clinical
phenotypes and in consequence would be useful for high-throughput screening of different
compounds. As was seen in [102], early pharmacological treatment would improve the
effectiveness of the drugs that could be tested and maybe reduced disease progression.
However, the creation of zebrafish models with CGG repeats would allow understanding
the function of expansion repeats in X-fragile syndrome and FXTAS.
4. Conclusions
The majority of the zebrafish models reviewed here of genes related to dominant
ataxia and X-fragile/FXTAS presented neural damage and/or locomotor deficits that re-
capitulate the human disorders. However, there are some models that did not develop
any neuronal or locomotor deficit: tbp morphants [78,79] and cancb4a and cancb4b mor-
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phants [91]. Nonetheless, tbp models were made of morpholinos and SCA17 is a gain of
function disorder but these studies helped to decipher tbp function in early development
and gene transcription [78,79]. Cancb4a and cancb4b models were generated with mor-
pholinos that revealed cancb4a and cancb4 functions in epiboly [91], although heterozygous
mutant models would have reproduced better the characteristics of episodic ataxia 5.
We should consider that most of the studies in zebrafish were performed with mor-
pholinos, which can sometimes cause off-target effects. It is necessary to validate them
with a control morpholino, mRNA rescue and Western blot/immunohistochemistry or RT-
qPCR. Furthermore, occasionally comparisons of a morphant model with their respective
mutant line revealed different phenotypes, which were usually milder in the case of mutant
animals. This can be caused by genetic compensation and maternally mRNA rescue in the
mutants. For that reason, is important and necessary to complement morpholino work
with mutant studies [103].
Recently developed CRISPR/Cas9 technology makes it possible to expand the number of
efficient specific zebrafish mutant lines to generate better models for human ataxias [20,104].
The study of heterozygous knock-out mutants would reproduce dominant ataxias caused
by missense mutations. However, in the dominant diseases of repeat expansions that are
caused by toxic gain of function mechanisms the creation of loss of function models by
knock-down or knock-out might not be the best approach. On the other hand, loss of
function models would make it possible to elucidate the function of the gene related to the
disorder. In addition, recent studies indicate that in repeat expansion neurodegenerative
syndromes a combination of gain of function and loss of function mechanisms might act
synergistically [105,106]. This could explain the neurodegenerative phenotypes observed
in most of the loss of function zebrafish models discussed here.
Knock-in models are more adequate for reproducing gain of function diseases. Nonethe-
less, the creation of knock-in models is difficult in zebrafish because it is necessary to
trigger homologous directed repair, which is much less efficient in these animals [21]. New
more effective knock-in techniques, such as the use of the CRISPR/Cpf1 system (instead of
CRISPR/Cas9), which leads to a fourfold increase of knock-in efficiency [107], would help
to establish the first knock-in zebrafish models of dominant ataxias.
Moreover, in expansion neuropathies, the injection of constructs with pathological re-
peats in zebrafish was found to be useful and revealed important data about toxicity and its
mechanisms. For example, Huntington disease was broadly studied injecting pathological
CAG expansions and these have allowed finding new possible treatments [108,109]. In this
review, we described some zebrafish transient models of dominant ataxias made with the
injection of pathological repeats that showed signs of neuropathy [38,48,50,51]. Moreover,
the first transgenic model of dominant ataxia was created with the pathological expansions
of SCA3 which had a locomotor deficit that was alleviated with chloroquine [51]. In the
future, it would be important to expand the range of zebrafish models of pathological
repeats for the study of different types of dominant ataxias. This could be applied to
develop the first zebrafish models of other frequent dominant ataxias in which a similar
zebrafish protein function was demonstrated, like SCA1 [110].
Zebrafish CNS organization allows the study of the cerebellum and its connections.
However, there are some differences between human and zebrafish brains: absence of corti-
cospinal and rubrospinal tracts in the zebrafish CNS [16], absence of the pons [111] and no
direct telencephalic projections to the spinal cord [112]. Another disadvantage of zebrafish
models is that 20 to 24% of zebrafish genes suffer a ray-finned fish whole genome dupli-
cation that generates genetic redundancy that could complicate model development [14].
Nonetheless, the advantages of zebrafish as a model for neuronal disorders are most rel-
evant than these disadvantages. One of these main advantages is its utility as a model
for high throughput screening of chemicals. In this review, we described some treatments
that were applied successfully to zebrafish models of dominant ataxias [51,57,60,90,92] and
X-fragile syndrome [102].
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Finally, almost all research done with the zebrafish model in this field has been
developed in embryos/larvae and there is a general lack of surveys in adult zebrafish
models of late onset dominant ataxias. These would be more informative in the pathogenic
functioning of the CNS because embryo/larvae models have not developed all neural
connections. Furthermore, it could facilitate the search for treatments that target early
pathological changes before the occurrence of toxicity and neuronal damage, which could
reduce disease progression. The development of resources and techniques for zebrafish
research will continue to enhance the utility of zebrafish for the study of human diseases
and particularly in neurodegenerative diseases like ataxias.
Supplementary Materials: The following are available online at https://www.mdpi.com/2073-440
9/10/2/421/s1, Table S1: Description of zebrafish models of autosomal dominant ataxias cited in
this article.
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